Coherus Hoping For Expedited FDA Review Of Pegfilgrastim On-Body
Biosimilar Humira Sales Won’t Accelerate Until 2025; Pleased With Ranibizumab Execution
Coherus BioSciences offered clarity and insight into its three marketed biosimilar products, as the firm continues to await USFDA approval for its pegfilgrastim biosimilar using an on-body injector device.
You may also be interested in...
Coherus BioSciences spoke at length about its two marketed biosimilars, referencing Neulasta and Lucentis, during the company’s first-quarter earnings call.
Generics Bulletin previews the most noteworthy and anticipated events for December 2023.
“A lot of companies are hurting because of the higher interest rates,” one major CEO observed recently, summing up a year which saw little headline-grabbing news on the M&A front for generic and biosimilar sponsors.